Medical/Pharmaceuticals

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192

* HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development of HL192 (ATH-399A) for the potential treatment of Parkinson's Disease in collaboration with NurrOn Pharmaceuticals. * The Phase 1 Study evaluates the safety, tolerability, and pharmacokinetics of ...

2023-10-12 19:00 1530

Scott's and 99Speedmart Join Forces to Launch Donation Campaign to Serve Underprivileged Children's Nutritional Needs

* One-month BUY1DONATE1 campaign to be rolled out nationwide, enabling anyone to take part in giving back * Donations of Scott's products to supplement the nutritional needs of 5,000 underprivileged children KUALA LUMPUR, Malaysia, Oct. 12, 2023 /PRNewswire/ -- Scott's, the market leader in t...

2023-10-12 18:56 2221

Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress

SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, has unveiled its phase III clinica...

2023-10-12 18:49 1516

Neoss® Group receives EU Medical Device Regulation (MDR) certifications for implants and abutments

ZÜRICH, Oct. 12, 2023 /PRNewswire/ -- Neoss Group, a leading innovator in dental implant solutions, is proud to announce that it has received EU Medical Device Regulation (MDR) certification by its Notified Body, the BSI Group, the Netherlands B.V. for its implants and abutments. This certificati...

2023-10-12 18:34 1543

So-Young Announces Board Change

BEIJING, Oct. 12, 2023 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that Mr.Min Yu, Mr. Xuejian ...

2023-10-12 18:00 3377

Prestigious World Congress of Neurology Returns In-Person to Convene World-Class Researchers in Montreal

MONTREAL, Oct. 12, 2023 /PRNewswire/ -- The World Federation of Neurology (WFN) and the Canadian Neurological Society (CNS) will host theXXVI World Congress of Neurology (WCN) in Montreal, Canada, from October 15 to 19, 2023. WCN is a major, biennial conference where world-class neurologists and ...

2023-10-12 18:00 1596

ALLORION THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 STUDY OF ARTS-021, A POTENTIAL BEST IN CLASS CDK2 INHIBITOR, FOR ADVANCED OR METASTATIC SOLID TUMORS

NATICK, Mass., Oct. 12, 2023 /PRNewswire/ -- Allorion Therapeutics (Allorion), a clinical-stage biotechnology company dedicated to the discovery and development of next-generation targeted drugs for cancer and autoimmune diseases, announced today the dosing of its first patient in the Phase 1/2 ...

2023-10-12 10:37 1647

Suvoda Introduces Advanced Drug Optimization For IRT to Improve Accuracy of Clinical Trial Drug Supply Management

Greater Control Over Drug Supply Management Helps Sponsors Reduce Costs and Carbon Footprint PHILADELPHIA, Oct. 12, 2023 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system (CNS), an...

2023-10-12 09:00 1974

Gencurix Receives Australian Government Approval for Droplex POLE Mutation Test

SEOUL, South Korea, Oct. 12, 2023 /PRNewswire/ -- Gencurix , a cancer molecular diagnostics company, has obtained approval from the Australian Government (The Department of Health and Aged Care, Therapeutic Goods Administration) for its Droplex POLE Mutati...

2023-10-12 06:00 2072

MicuRx announces poster presentation and participation in ID Week 2023 Conference

FOSTER CITY, Calif., Oct. 11, 2023 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, announces that a poster on our preclinical product, MRX-6038, will be p...

2023-10-11 23:33 1793

SINGAPORE AND JAPAN CLINICIAN-SCIENTISTS COLLABORATE ON GROUNDBREAKING TELESURGERY TRIAL SPANNING OVER 5,000KM

This preclinical trial surgery involves clinician-scientists in NUS Medicine and theNational University Hospital in partnership with Fujita Health University SINGAPORE, Oct. 11, 2023 /PRNewswire/ -- Singapore's National University Hospital (NUH) and the Yong Loo Lin School of Medicine at theNatio...

2023-10-11 22:13 2725

Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China

SUZHOU, China, Oct. 11, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that its Hedgehog/SMO inhibitor GT1708F had obtained conditional appr...

2023-10-11 17:20 1660

KHB Becomes First Chinese Company to Obtain EU Class D IVDR Certification for Its Rapid Test HIV Colloidal Gold Diagnostic Kit

SHANGHAI, Oct. 11, 2023 /PRNewswire/ -- Shanghai Kehua Bio-engineering Co., Ltd ("KHB" or "the Company", Stock code: 002022.SZ),China's leading In Vitro Diagnostic (IVD) company has achieved a significant milestone by becoming the first Chinese company to obtain EU Clas...

2023-10-11 16:27 2621

Smith+Nephew opens new state-of-the-art surgical innovation and training centre in the heart of Munich

LONDON, Oct. 11, 2023 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company specialising in orthopaedics, advanced wound management and sports medicine, is pleased to announce the opening of the purpose-built Smith+Nephew Academy Munich, a new centre for surgica...

2023-10-11 14:00 3406

TaiGen Enters Exclusive License Agreement with YSP

TAIPEI, Oct. 10, 2023 /PRNewswire/ -- TaiGen Biopharmaceuticals Holdings Ltd. ("TaiGen") announces that TaiGen Biotechnology, a subsidiary company of TaiGen, have signed an exclusive licensing agreement with Y.S.P. Industries (M) Sdn. Bhd. to develop and commercialize TaiGen's new drug inMalaysia...

2023-10-11 11:24 1698

GC Biopharma Shares its Successful HR System Transformation at SAP Success Connect 2023

YONGIN, South Korea, Oct. 10, 2023 /PRNewswire/ -- GC Biopharma Corp. announced today that it has presented the successful adoption of SAP SuccessFactor Work Zone, which is a cloud-based HR solution by SAP, at the SAP Success Connect 2023 held onOctober 3rd in Las Vegas. SAP Success Connect is...

2023-10-11 08:49 1688

Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023

HANGZHOU and SHAOXING, China, Oct. 11, 2023  /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of Phase II study topline results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the European Academy of Der...

2023-10-11 08:10 2215

VISTA Eye Specialist Achieves International Recognition at European Congress

PETALING JAYA, Malaysia, Oct. 11, 2023 /PRNewswire/ -- Last September, VISTA Eye Specialist proudly marked its presence at the prestigious European Society of Cataract and Refractive Surgery (ESCRS) Symposium and Congress inVienna, Austria. This event, the second participation since the onset of ...

2023-10-11 08:00 2070

EADV Congress: Non-melanoma skin cancer killing more people than melanoma, new study finds

BERLIN, Oct. 11, 2023 /PRNewswire/ -- Non-melanoma skin cancer (NMSC) is causing a greater number of global deaths than melanoma, the more serious form of skin cancer, a new study presented today at the EADV Congress 2023 has found. Researchers also believe that NMSC is underreported and that the...

2023-10-11 06:01 1919

SAFETYscan47: A Valuable Component in Revolutionizing Chemical Risk Assessments for Global Health and Safety

SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, today announced its SAFETYscan®47 platform as a New Approach Methodology (NAM), part of a standardized framework aiming to revolutionize chemical risk a...

2023-10-10 23:10 2011
1 ... 150151152153154155156 ... 617